Analysis
Apnimed, a Shionogi-backed clinical-stage biotech, launched a $150 million IPO Monday for AD109, an experimental once-daily pill that would become the first FDA-approved treatment for obstructive sleep apnea if approved. The company is offering 10 million shares at $14 to $16 apiece, implying a market capitalization near $570 million at the midpoint, with BofA Securities, Evercore ISI, Cantor and LifeSci Capital serving as joint book-runners.
AD109, also known as Oxnimbi, is Apnimed's sole clinical candidate -- a fixed-dose combination pill that has been evaluated in roughly 1,300 patients across several Phase 3 trials. An FDA approval decision is expected around February 2027, meaning the IPO is effectively a pre-approval financing round conducted in public markets rather than a typical revenue-generating biotech debut. Apnimed has also separately secured up to $150 million in debt financing from Healthcare Royalty Partners specifically earmarked to support a planned commercial launch of AD109, layering non-dilutive capital on top of the equity raise to fund the go-to-market push that would follow approval.
Obstructive sleep apnea currently has no approved pharmaceutical treatment -- existing options are limited to devices like CPAP machines and surgical interventions, both with well-documented patient adherence problems. A first-to-market oral pill addresses a large, underserved patient population, which is the core commercial thesis underlying the offering, though it remains entirely conditional on FDA approval roughly a year and a half from now.
The IPO lands in the middle of a genuinely active 2026 for biotech listings -- Scribe Therapeutics, the Eli Lilly-backed gene-editing company, saw its shares jump nearly 49% on its own NASDAQ debut just days earlier, part of what analysts describe as biotech's strongest first-half fundraising performance since 2022, driven heavily by megarounds and now flowing into a healthier IPO window.
What to watch: where Apnimed prices within its $14-$16 range when the deal is finalized Thursday night, how the stock performs in its Friday NASDAQ debut relative to Scribe Therapeutics' strong pop, and whether the February 2027 FDA decision timeline holds given AD109 is the entire investment thesis behind the company's valuation.
